Zurcher Kantonalbank Zurich Cantonalbank Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 364,776 shares of the medical equipment provider’s stock after buying an additional 10,049 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.16% of Hologic worth $26,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. General Partner Inc. purchased a new position in Hologic during the fourth quarter valued at $26,000. Groupama Asset Managment lifted its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Stephens restated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Trading Down 4.6 %

Shares of HOLX stock opened at $62.59 on Wednesday. The stock has a market capitalization of $14.04 billion, a P/E ratio of 19.74, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm’s 50 day moving average is $67.87 and its 200 day moving average is $75.04. Hologic, Inc. has a 12-month low of $61.70 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.